###begin article-title 0
NOD2 regulates hematopoietic cell function during graft-versus-host disease
###end article-title 0
###begin p 1
K. Brandl's present address is Dept. of Genetics, the Scripps Research Institute, La Jolla, CA 92037.
###end p 1
###begin p 2
###xml 452 455 452 455 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
Nucleotide-binding oligomerization domain 2 (NOD2) polymorphisms are independent risk factors for Crohn's disease and graft-versus-host disease (GVHD). In Crohn's disease, the proinflammatory state resulting from NOD2 mutations have been associated with a loss of antibacterial function of enterocytes such as paneth cells. NOD2 has not been studied in experimental allogeneic bone marrow transplantation (allo-BMT). Using chimeric recipients with NOD2-/- hematopoietic cells, we demonstrate that NOD2 deficiency in host hematopoietic cells exacerbates GVHD. We found that proliferation and activation of donor T cells was enhanced in NOD-deficient allo-BMT recipients, suggesting that NOD2 plays a role in the regulation of host antigen-presenting cells (APCs). Next, we used bone marrow chimeras in an experimental colitis model and observed again that NOD2 deficiency in the hematopoietic cells results in increased intestinal inflammation. We conclude that NOD2 regulates the development of GVHD through its inhibitory effect on host APC function.
###end p 2
###begin p 3
###xml 151 170 151 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib2">Bertin et al., 1999</xref>
###xml 172 192 172 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">Inohara et al., 2001</xref>
###xml 551 574 551 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">Inohara and Nunez, 2003</xref>
Nucleotide-binding oligomerization domain 2 (NOD2) belongs to the family of intracellular NOD-like receptors, which are present in various cell types (Bertin et al., 1999; Inohara et al., 2001). NOD2 has a C-terminal leucine-rich repeat region for sensing microbial products, a central nucleotide-binding domain (NACHT), and an N-terminal CARD (caspase activation and recruitment domain). NOD2 detects muramyl dipeptide (MDP), a molecule which is produced during the synthesis and degradation of peptidoglycan, a cell wall component of most bacteria (Inohara and Nunez, 2003). Stimulation of NOD2 induces recruitment of Rip2 (also called RICK) at the N-terminal CARD domain. Activation of Rip2 leads to subsequent steps that ultimately result in activation and nuclear translocation of NF-kappaB and transcription of its target genes.
###end p 3
###begin p 4
###xml 293 311 293 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">Hugot et al., 2001</xref>
###xml 313 331 313 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">Ogura et al., 2001</xref>
###xml 437 464 437 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">Miceli-Richard et al., 2001</xref>
###xml 495 516 495 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">Kanazawa et al., 2005</xref>
###xml 706 729 706 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">Kobayashi et al. (2005)</xref>
###xml 785 807 785 807 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Listeria monocytogenes</italic>
###xml 918 921 914 917 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 928 949 924 945 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">Watanabe et al. (2004</xref>
###xml 951 955 947 951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib25">2006</xref>
###xml 1023 1026 1019 1022 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1104 1123 1100 1119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib16">Maeda et al. (2005)</xref>
###xml 25 30 <span type="species:ncbi:9606">human</span>
###xml 54 59 <span type="species:ncbi:10090">mouse</span>
###xml 785 807 <span type="species:ncbi:1639">Listeria monocytogenes</span>
###xml 922 926 <span type="species:ncbi:10090">mice</span>
###xml 1027 1031 <span type="species:ncbi:10090">mice</span>
###xml 1167 1172 <span type="species:ncbi:10090">mouse</span>
###xml 1183 1188 <span type="species:ncbi:10090">mouse</span>
###xml 1205 1210 <span type="species:ncbi:9606">human</span>
NOD2 has been studied in human Crohn's disease and in mouse models for inflammatory bowel disease. Single nucleotide polymorphisms (SNPs) near, or within, the NOD2 leucine-rich repeat region (G908R, L1007insC, and R702W) constitute genetic risk factors for the development of Crohn's disease (Hugot et al., 2001; Ogura et al., 2001). Mutations in the NACHT region of NOD2 are linked to other inflammatory diseases such as Blau syndrome (Miceli-Richard et al., 2001) and early onset sarcoidosis (Kanazawa et al., 2005). Several groups have investigated the role of NOD2 in experimental models for intestinal inflammation, which has led to the development of three hypotheses regarding the function of NOD2. Kobayashi et al. (2005) found greater susceptibility to enteral infection with Listeria monocytogenes and reduced expression of alpha defensins, antibacterial peptides produced by intestinal Paneth cells, in NOD2-/- mice. Watanabe et al. (2004, 2006) demonstrated increased sensitivity to experimental colitis in NOD2-/- mice, which was driven by T helper type 1 cells and increased IL-12 release. Maeda et al. (2005) created a knockout/knockin transgenic NOD2 mouse using the mouse equivalent to a human mutation (L1007insC) and found abundant IL-1beta production in response to MDP. Collectively, these experimental data do not allow for one unified conclusion regarding the mechanism of NOD2-mediated regulation of inflammatory diseases.
###end p 4
###begin p 5
###xml 331 350 331 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">Holler et al. (2004</xref>
###xml 352 356 352 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">2006</xref>
###xml 600 624 600 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">Elmaagacli et al. (2006)</xref>
###xml 826 845 826 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">Mayor et al. (2007)</xref>
###xml 976 995 976 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">Holler et al., 2008</xref>
###xml 1214 1219 <span type="species:ncbi:10090">mouse</span>
Recently, SNPs in the NOD2 gene locus have been linked to graft-versus-host disease (GVHD), which is the major complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). GVHD is a systemic inflammatory disease caused by alloreactive donor T cells and characterized by tissue damage in gut, liver, and skin. Holler et al. (2004, 2006) found an association between SNPs (alleles 8, 12, and 13) of the NOD2 gene in the donor or host and a higher incidence of GVHD, as well as increased transplant-related mortality. Interestingly, these findings were only partially confirmed by Elmaagacli et al. (2006), who also found an increased incidence of GVHD when NOD2 SNPs were present in both the donor and recipient but reduced incidence of GVHD when the NOD2 SNPs were present in the donor only. In addition, Mayor et al. (2007) connected NOD2 SNPs with an increased leukemia relapse rate after allo-HSCT, which could not be confirmed by other investigators (Holler et al., 2008). Collectively, it appears that NOD2 SNPs of allo-HSCT recipients influence posttransplant immunity; however, the underlying mechanism is unclear. In the present study, we aim to clarify the underlying role of NOD2 in mouse models for allogenic BM transplantation (allo-BMT), colitis, and tumors.
###end p 5
###begin title 6
RESULTS AND DISCUSSION
###end title 6
###begin title 7
NOD2 deficiency in donor BM cells and/or donor T cells does not affect the development of GVHD
###end title 7
###begin p 8
###xml 116 135 116 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">Holler et al., 2004</xref>
###xml 137 141 137 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">2006</xref>
###xml 163 186 163 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">Elmaagacli et al., 2006</xref>
###xml 394 397 394 397 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 487 495 487 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 A</xref>
###xml 517 525 517 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 B</xref>
###xml 576 584 576 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 C</xref>
###xml 648 649 648 649 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 675 678 675 678 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 843 846 843 846 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 856 864 856 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 D</xref>
###xml 969 972 969 972 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1289 1290 1289 1290 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 1305 1306 1303 1304 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sup>
###xml 1470 1473 1468 1471 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1665 1668 1663 1666 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1682 1685 1680 1683 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1710 1713 1708 1711 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1723 1726 1721 1724 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1736 1744 1734 1742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 E</xref>
###xml 1939 1940 1937 1938 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 1951 1952 1947 1948 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 1955 1963 1951 1959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 E</xref>
###xml 2409 2432 2405 2428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">Dabbagh and Lewis, 2003</xref>
###xml 2434 2452 2430 2448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib3">Caron et al., 2005</xref>
###xml 2454 2479 2450 2475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib15">MacLeod and Wetzler, 2007</xref>
To address contradictory clinical studies showing that NOD2 SNPs of the allo-HSCT donor can either exacerbate GVHD (Holler et al., 2004, 2006) or ameliorate GVHD (Elmaagacli et al., 2006), we investigated the effect of NOD2 deficiency of allo-BMT donors in our GVHD models. We first assessed whether NOD2 deficiency affects allogeneic donor T cells. We transferred CFSE-labeled B6 WT or B6 NOD2-/- T cells to lethally irradiated BALB/c recipients and found similar T cell proliferation (Fig. 1 A), T cell activation (Fig. 1 B), and expression of the gut-homing molecule LPAM (Fig. 1 C). Next, we performed mixed leukocyte reactions (MLRs) using CD5+-selected B6 WT or B6 NOD2-/- splenocytes as effectors and irradiated BALB/c splenocytes as stimulators. We found no significant differences in the proliferation rate between WT T cells and NOD2-/- T cells (Fig. 1 D). In addition, we found no significant differences in the proliferation rate between WT T cells and NOD2-/- T cells when we added different toll-like receptor (TLR) and NOD2 ligands (MDP, LPS, Pam3Cys, Flagellin, and PGN) alone or in combination with the MLRs (unpublished data). To determine the effect of NOD2 deficiency in allo-BMT donors on the development of GVHD, we first used an MHC-disparate allo-BMT model, B6 (H-2b)-->BALB/c (H-2d). Lethally irradiated recipients received T cell-depleted BM (TCD-BM), and GVHD was induced by the addition of donor splenic T cells to the allograft. We used NOD2-/- donors and WT donors as the source for TCD-BM or T cells. We did not detect significant differences in lethal GVHD between the four different groups receiving WT BM + WT T cells, WT BM + NOD2-/- T cells, NOD2-/- BM + WT T cells, or NOD2-/- BM + NOD2-/- T cells (Fig. 1 E, left). To confirm that our observations were not strain dependent or model dependent, we performed similar experiments in an MHC-matched model with minor histocompatibility disparities, B6 (H-2b)-->LP (H-2b) (Fig. 1 E, right). We conclude that NOD2 deficiency of the allo-BMT donor (either donor T cells or BM) has no significant impact on the development of GVHD and does not regulate alloactivation of donor T cells. Our data suggest that NOD2 has no cell-intrinsic role in the regulation of T cell activity during GVHD despite the increasing evidence that innate immune receptors, such as TLRs, can modulate T cell function and activation during inflammation (Dabbagh and Lewis, 2003; Caron et al., 2005; MacLeod and Wetzler, 2007).
###end p 8
###begin p 9
###xml 0 95 0 95 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NOD2 deficiency in donor BM cells and/or donor T cells does not affect the development of GVHD.</bold>
###xml 173 174 173 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 204 207 204 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 210 211 210 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 286 287 286 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 409 412 409 412 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 474 478 474 478 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 487 490 487 490 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 600 603 600 603 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 706 709 706 709 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 752 755 752 755 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 758 759 758 759 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 861 862 861 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 977 978 977 978 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1006 1009 1006 1009 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1023 1024 1023 1024 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1053 1056 1053 1056 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1125 1126 1125 1126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
NOD2 deficiency in donor BM cells and/or donor T cells does not affect the development of GVHD. (A-C) Lethally irradiated (8.5 Gy) BALB/c allo-BMT recipients received 5 x 106 CFSE-labeled B6 WT or B6 NOD2-/-CD5+ T cells. Recipient spleens were harvested 96 h after transfer of T cells; n = 8/group; combined data from two independent experiments are shown. (A) Identical CFSE histogram overlays of WT and NOD2-/- donor T cells (left), as well as similar total number of CFSEhigh and CFSElow donor T cells. (B) Similar up-regulation of the alloactivation marker CD25 on WT B6 donor T cells versus NOD2-/- donor T cells. (C) Similar expression of the gut-homing marker LPAM on WT B6 donor T cells versus NOD2-/- donor T cells. (D) MLR with WT versus NOD2-/-CD5+ T cells and irradiated BALB/c stimulators. Combined data of three independent experiments are shown; n = 12/group. (E) Lethally irradiated BALB/c (8.5 Gy) or LP (11Gy) allo-BMT recipients were transplanted with 5 x 106 B6 WT TCD-BM versus B6 NOD2-/- TCD-BM and 106 B6 WT T cells versus B6 NOD2-/- T cells. Combined data from four independent experiments are shown; n = 15-45/group. Error bars indicate SEM.
###end p 9
###begin title 10
###xml 4 7 4 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
NOD2-/- allo-BMT recipients have increased systemic and target organ GVHD
###end title 10
###begin p 11
###xml 117 118 117 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k</sup>
###xml 129 130 127 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 189 192 187 190 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 257 265 255 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 A</xref>
###xml 328 329 326 327 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 340 341 336 337 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 350 358 346 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 A</xref>
###xml 561 564 557 560 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 596 604 592 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 B</xref>
###xml 658 659 654 655 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 712 715 708 711 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 737 752 733 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2, C and D</xref>
###xml 912 913 908 909 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 917 918 913 914 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 953 956 949 952 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 978 986 974 982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 E</xref>
###xml 1041 1063 1037 1059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">Hollander et al., 1994</xref>
###xml 1296 1315 1292 1311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">Holler et al., 2004</xref>
###xml 1317 1321 1313 1317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">2006</xref>
###xml 1677 1695 1673 1691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">Hugot et al., 2001</xref>
###xml 1697 1718 1693 1714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">Watanabe et al., 2004</xref>
###xml 1720 1724 1716 1720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib25">2006</xref>
###xml 1726 1730 1722 1726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib26">2008</xref>
###xml 1732 1754 1728 1750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">Kobayashi et al., 2005</xref>
###xml 1361 1367 <span type="species:ncbi:9606">humans</span>
###xml 1617 1621 <span type="species:ncbi:10090">mice</span>
###xml 1626 1629 <span type="species:ncbi:9606">men</span>
###xml 1904 1908 <span type="species:ncbi:10090">mice</span>
###xml 1983 1987 <span type="species:ncbi:10090">mice</span>
To investigate the role of NOD2 in regulating GVHD in allo-BMT recipients, we first used the MHC-disparate B10BR (H-2k)-->B6 (H-2b) model. We found significantly more lethal GVHD in B6 NOD2-/- allo-BMT recipients as compared with B6 WT allo-BMT recipients (Fig. 2 A, left). We confirmed these findings in the MHC-matched LP (H-2b)-->B6 (H-2b) model (Fig. 2 A, right). To analyze target organ GVHD, we performed histopathological analyses and found significantly more GVHD in the terminal ileum, colon, and liver, as well as a trend toward more skin GVHD in NOD2-/- versus WT allo-BMT recipients (Fig. 2 B). The numbers of tissue-infiltrating alloreactive CD3+ T cells in GVHD target organs were increased in NOD2-/- allo-BMT recipients (Fig. 2, C and D). To investigate thymic GVHD, we determined the number of thymocytes and their subsets at day 21 after allo-BMT. We found a significantly reduced number of CD4+/CD8+ double-positive thymocytes in NOD2-/- allo-BMT recipients (Fig. 2 E), which is the characteristic feature of thymic GVHD (Hollander et al., 1994). We conclude that NOD2 deficiency in allo-BMT recipients exacerbates systemic and organ GVHD. Our results are in agreement with clinical data connecting NOD2 SNPs in allo-BMT recipients to increased incidence and severity of GVHD (Holler et al., 2004, 2006). A limitation of our study is that in humans the association between NOD2 and GVHD was observed in individuals with heterozygous SNPs, whereas our studies used homozygous NOD2-deficient allo-BMT recipients to investigate the effect of NOD2 deficiency during GVHD. This is similar to studies in mice and men regarding the role of NOD2 in Crohn's disease (Hugot et al., 2001; Watanabe et al., 2004, 2006, 2008; Kobayashi et al., 2005). NOD2 polymorphisms resulting in impaired NOD2 function were associated with increased susceptibility to Crohn's disease. Studies in NOD2-deficient mice demonstrated an increased susceptibility to experimental colitis, whereas mice with a NOD2 transgene resulting in increased NOD2 function were resistant to experimental colitis.
###end p 11
###begin p 12
###xml 4 7 4 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 0 153 0 153 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NOD2<sup>&#8722;/&#8722;</sup> allo-BMT recipients have increased systemic and target organ GVHD because of enhanced activation and proliferation of alloreactive donor T cells.</bold>
###xml 206 209 206 209 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 245 246 245 246 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 269 270 269 270 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 299 300 299 300 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 324 325 324 325 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 397 398 397 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 465 468 465 468 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 504 505 504 505 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 523 524 523 524 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 646 647 646 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 739 742 739 742 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 771 772 771 772 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 868 871 868 871 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 980 981 976 977 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1031 1034 1027 1030 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1093 1094 1089 1090 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1098 1099 1094 1095 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1195 1196 1191 1192 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1200 1201 1196 1197 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1211 1212 1207 1208 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1216 1217 1212 1213 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1223 1224 1219 1220 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1233 1234 1229 1230 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1299 1302 1295 1298 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1338 1339 1334 1335 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1362 1363 1358 1359 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1438 1439 1434 1435 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1587 1590 1583 1586 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1775 1778 1771 1774 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1858 1861 1854 1857 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1911 1912 1907 1908 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1930 1931 1926 1927 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 2053 2054 2049 2050 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 2115 2116 2111 2112 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2130 2131 2126 2127 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2179 2180 2175 2176 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2193 2194 2189 2190 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
NOD2-/- allo-BMT recipients have increased systemic and target organ GVHD because of enhanced activation and proliferation of alloreactive donor T cells. (A) Lethally irradiated (11 Gy) B6 WT versus B6 NOD2-/- allo-BMT recipients received 5 x 106 B10BR TCD-BM or 5 x 106 LP TCD-BM with or without 106 B10BR T cells or 2 x 106 LP T cells. Combined data from four independent experiments are shown; n = 45/group. (B-E) Lethally irradiated (11 Gy) B6 WT versus B6 NOD2-/- allo-BMT recipients received 5 x 106 B10BR TCD-BM + 106 B10BR T cells. Organs were harvested at day 21 after allo-BMT. Combined data from two independent experiments are shown; n = 10/group. (B) Histopathologic GVHD scores in target organs showing increased GVHD in NOD2-/- allo-BMT recipients. (C) CD3+ histochemistry images showing increased infiltration of T cells (brown) in liver tissue of NOD2-/- allo-BMT recipients. Bars, 50 microm. (D) Quantification of T cell infiltration in GVHD target organs by CD3+ histochemistry. (E) Increased thymic GVHD in NOD2-/- allo-BMT recipients demonstrated by reduced numbers of CD4+/CD8+ double-positive thymocytes. Shown are flow cytometric plots and the absolute numbers of DP (CD4+/CD8+), DN (CD4-/CD8-), CD4+, and CD8+ thymocytes. (F) Lethally irradiated (11 Gy) B6 WT versus B6 NOD2-/- allo-BMT recipients received 5 x 106 CFSE-labeled B10BR CD5+ T cells. Recipient spleens were harvested 96 h after transfer of T cells; n = 8/group; combined data from two independent experiments are shown. CFSE histogram overlays of donor T cells in WT allo-BMT recipients versus NOD2-/- allo-BMT recipients (left); ratio of proliferating donor T cells (right, top) and absolute numbers of donor T cells (right, bottom) showing increased donor T cell proliferation in NOD2-/- allo-BMT recipients. (G and H) Lethally irradiated (11 Gy) B6 WT versus B6 NOD2-/- allo-BMT recipients were transplanted with 5 x 106 B10BR TCD-BM + 106 B10BR T cells. Organs were harvested at day 14 after allo-BMT. Combined data from two independent experiments are shown; n = 10/group. (G) Absolute numbers and activation status (CD25+) of donor CD3+ T cells in spleen and MLNs. Percentage of FoxP3+ cells in CD4+ splenocytes (top right) and expression of the gut homing marker LPAM in MLNs (bottom right) are shown. (H) Absolute numbers of donor B cells, NK cells, monocytes, DCs, and granulocytes in spleen. Error bars indicate SEM.
###end p 12
###begin title 13
###xml 83 86 83 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
The activation and proliferation of alloreactive donor T cells is increased in NOD2-/- allo-BMT recipients
###end title 13
###begin p 14
###xml 57 60 57 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 162 165 162 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 292 295 292 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 317 325 317 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 F</xref>
###xml 541 544 539 542 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 566 574 564 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 G</xref>
###xml 614 615 612 613 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 629 630 627 628 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 648 649 646 647 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 655 656 653 654 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 865 886 863 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1">Alpdogan et al., 2003</xref>
###xml 959 962 957 960 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1024 1032 1022 1030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 G</xref>
###xml 1065 1066 1063 1064 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1070 1071 1068 1069 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1158 1159 1156 1157 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1163 1164 1161 1162 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1184 1185 1182 1183 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1206 1209 1204 1207 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1231 1239 1229 1237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 G</xref>
###xml 1277 1278 1275 1276 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1281 1282 1279 1280 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1293 1294 1287 1288 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1297 1298 1291 1292 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1308 1309 1302 1303 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1312 1313 1306 1307 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1486 1489 1473 1476 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1518 1526 1505 1513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 G</xref>
###xml 1658 1661 1645 1648 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1683 1691 1670 1678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 H</xref>
###xml 1733 1736 1720 1723 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
To study the mechanisms underlying increased GVHD in NOD2-/- allo-BMT recipients, we first transferred CFSE-labeled allogeneic B10BR T cells into B6 WT or B6 NOD2-/- allo-BMT recipients. We found that the in vivo proliferation of alloreactive donor T cells was significantly increased in NOD2-/- allo-BMT recipients (Fig. 2 F). Next, we performed allo-BMTs in the B10BR-->B6 model and harvested organs at day 14 after allo-BMT. We found that the number of donor T cells was significantly increased in spleen and mesenteric LNs (MLNs) in NOD2-/- allo-BMT recipients (Fig. 2 G, left). However, the percentages of CD4+ T cells, CD8 + T cells, and CD44+/CD62L- effector T cells were not significantly different (). We next determined the alloactivation status of donor T cells by their CD25 expression, which is a reliable marker for alloactivation in our GVHD models (Alpdogan et al., 2003), and found that donor T cells were significantly more activated in NOD2-/- allo-BMT recipients as compared with WT allo-BMT recipients (Fig. 2 G, middle). When we analyzed FoxP3+/CD4+ regulatory T cells in the spleen, we found a significantly reduced percentage of FoxP3+/CD4+ cells (of total CD4+ splenocytes) in NOD2-/- allo-BMT recipients (Fig. 2 G, top right). The percentages of IL-17+CD4+, IFN-gamma+CD4+, and Tbet+CD4+ T cells were not different (Fig. S1). There was no difference between the expression of the gut-homing molecule LPAM (alpha4beta7 integrin) on donor T cells in MLNs in NOD2-/- and WT allo-BMT recipients (Fig. 2 G, bottom right). We detected no differences in donor cell types, such as B cells, NK cells, granulocytes, monocytes, and DCs in NOD2-/- allo-BMT recipients (Fig. 2 H). We conclude that increased GVHD in NOD2-/- allo-BMT recipients is the result of enhanced alloactivation and proliferation of donor T cells.
###end p 14
###begin title 15
NOD2 deficiency in the hematopoietic system of the allo-BMT recipient exacerbates GVHD
###end title 15
###begin p 16
###xml 478 481 478 481 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 519 522 517 520 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 530 533 528 531 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 555 556 551 552 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 786 789 782 785 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 866 869 860 863 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 878 881 872 875 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 991 994 981 984 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1025 1033 1015 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 A</xref>
###xml 1107 1115 1095 1103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 A</xref>
###xml 1282 1285 1270 1273 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1336 1339 1320 1323 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1370 1378 1354 1362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 B</xref>
###xml 1419 1420 1403 1404 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1473 1476 1457 1460 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1512 1520 1494 1502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 C</xref>
###xml 1623 1626 1605 1608 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1662 1670 1642 1650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 D</xref>
###xml 1836 1839 1816 1819 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1900 1903 1876 1879 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1934 1942 1910 1918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 D</xref>
###xml 2019 2020 1995 1996 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2024 2025 2000 2001 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2079 2080 2055 2056 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2093 2094 2069 2070 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2115 2118 2091 2094 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 2154 2162 2128 2136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 D</xref>
###xml 2274 2282 2248 2256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 D</xref>
###xml 2493 2496 2467 2470 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 557 561 <span type="species:ncbi:10090">mice</span>
###xml 772 776 <span type="species:ncbi:10090">mice</span>
###xml 790 794 <span type="species:ncbi:10090">mice</span>
Given that NOD2 is expressed in both hematopoietic and nonhematopoietic cells types, including antigen-presenting cells and intestinal epithelial cells, respectively, it is not clear what relative contributions of these cells types is to the development of GVHD. To address this, we created BM chimeras in which the NOD2 deficiency was only manifest in one of these systems. BM chimeras were created by performing syngeneic BMTs after lethal irradiation, using B6 WT and B6 NOD2-/- as donors or as recipients (WT-->NOD2-/- or NOD2-/--->WT). Using B6 Ly5.1+ mice as donors, we found the donor chimerism of hematopoietic cell subsets to be >95% in GVHD target organs, as well as in secondary lymphoid organs at day 90 after syngeneic BMT (). We then used the BM chimera, WT mice, and NOD2-/- mice as allo-BMT recipients in the B10BR-->B6 GVHD model. We found that NOD2-/- and NOD2-/--->WT chimeric allo-BMT recipients had a greater GVHD-induced mortality rate as compared with WT and WT-->NOD2-/- chimeric allo-BMT recipients (Fig. 3 A, left). We confirmed our findings in the minor mismatched LP-->B6 model (Fig. 3 A, right). To analyze target organ GVHD, we performed histopathological analyses and found significantly more GVHD in the terminal ileum, colon, liver, and skin in NOD2-/--->WT chimeric allo-BMT recipients versus WT-->NOD2-/- chimeric allo-BMT recipients (Fig. 3 B). The numbers of tissue-infiltrating CD3+ T cells in GVHD target organs were increased in NOD2-/--->WT chimeric allo-BMT recipients (Fig. 3 C). We found that the number of donor T cells was significantly increased in the spleen and MLNs in NOD2-/--->WT chimeric allo-BMT recipients (Fig. 3 D, left). We next determined the alloactivation status of donor T cells by their CD25 expression and found that donor T cells were significantly more activated in NOD2-/--->WT chimeric allo-BMT recipients as compared with WT-->NOD2-/- chimeric allo-BMT recipients (Fig. 3 D, middle). Additionally, we found a significantly reduced percentage of FoxP3+/CD4+ regulatory T cells in the spleen (percentage of FoxP3+ in total CD4+ splenocytes) in NOD2-/--->WT chimeric allo-BMT recipients (Fig. 3 D, top right). The expression of LPAM on donor T cells in MLNs was similar in both chimeric allo-BMT recipients (Fig. 3 D, bottom right). We conclude that NOD2 deficiency in the hematopoietic system exacerbates GVHD, whereas NOD2 deficiency in the nonhematopoietic system has no significant impact on the development of GVHD in NOD2-/- allo-BMT recipients.
###end p 16
###begin p 17
###xml 0 86 0 86 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NOD2 deficiency of the hematopoietic system of the allo-BMT recipient aggravates GVHD.</bold>
###xml 243 246 241 244 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 257 260 255 258 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 331 334 327 330 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 400 401 396 397 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 424 425 420 421 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 444 445 440 441 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 469 470 465 466 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 562 563 558 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 625 628 619 622 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 639 642 633 636 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 709 710 701 702 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 728 729 720 721 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 851 852 843 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 989 990 981 982 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1054 1055 1046 1047 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1069 1070 1061 1062 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1118 1119 1110 1111 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 102 106 <span type="species:ncbi:10090">mice</span>
NOD2 deficiency of the hematopoietic system of the allo-BMT recipient aggravates GVHD. (A-D) Chimeric mice with NOD2 deficiency either in the hematopoietic system or in the nonhematopoietic system were created by syngeneic BMT (B6 WT-->B6 NOD2-/- or B6 NOD2-/--->B6 WT). After 90 d, lethally irradiated (11 Gy) B6 WT versus B6 NOD2-/- versus chimeric allo-BMT recipients were transplanted with 5 x 106 B10BR TCD-BM or 5 x 106 LP TCD-BM + 2 x 106 B10BR T cells or 3 x 106 LP T cells. (A) Survival curves. Combined data from two independent experiments are shown; n = 16/group. (B-E) Lethally irradiated (11 Gy) B6 WT-->B6 NOD2-/- or B6 NOD2-/--->B6 WT chimeric allo-BMT recipients were transplanted with 5 x 106 B10BR TCD-BM + 106 B10BR T cells. Organs were harvested at day 14 after allo-BMT. Combined data from two independent experiments are shown; n = 8/group. (B) Histopathologic GVHD scores in GVHD target organs. (C) Quantification of T cell infiltration in GVHD target organs by CD3+ histochemistry. (D) Absolute number and activation status (CD25+) of donor CD3+ T cells in spleen and MLNs, percentage of FoxP3+ regulatory T cells (top right), and expression of the gut-homing marker LPAM in MLNs (bottom right). Error bars indicate SEM.
###end p 17
###begin title 18
###xml 4 7 4 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
NOD2-/- DCs have a higher activation status and increased ability to induce T cell proliferation during GVHD
###end title 18
###begin p 19
###xml 166 169 166 169 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 526 529 524 527 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 551 559 549 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 A</xref>
###xml 685 686 683 684 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 690 691 688 689 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 825 828 823 826 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 868 883 866 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4, B and C</xref>
###xml 1101 1104 1099 1102 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1202 1205 1200 1203 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1328 1336 1326 1334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 D</xref>
###xml 1527 1530 1525 1528 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1792 1811 1790 1809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">Holler et al., 2004</xref>
###xml 1813 1817 1811 1815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">2006</xref>
###xml 1819 1842 1817 1840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">Elmaagacli et al., 2006</xref>
Based upon our finding that donor T cell proliferation is increased in allo-BMT recipients with NOD2 deficiency in the hematopoietic system, we hypothesized that NOD2-/- DCs might have a higher activation status and increased ability to induce T cell proliferation during GVHD. We therefore performed allo-BMTs in the B10BR-->B6 model and harvested spleens at day 7 after allo-BMT. We found that the absolute numbers of host DC subsets in the spleen were not significantly different before and after allo-BMT in WT versus NOD2-/- allo-BMT recipients (Fig. 4 A). We then quantified the expression of the activation markers and costimulatory molecules CD40, CD80, and CD86 on host (CD11c+H2kb+) DCs before allo-BMT and at day 7 after allo-BMT. We found a significantly increased up-regulation of activation markers on host NOD2-/- DCs in contrast to WT DCs during GVHD (Fig. 4, B and C). The increase in the expression of MHC class II molecules, which was already high at baseline, did not reach statistical significance (unpublished data). To study DC function, we selected splenic DCs from WT and NOD2-/- allo-BMT recipients with GVHD (day 7) and used them as stimulators in MLRs. We found that B6 NOD2-/- DCs had a significantly increased ability to induce proliferation of allogeneic B10BR T cells as compared with B6 WT DCs (Fig. 4 D). These data supports the hypothesis that NOD2 can negatively regulate the activity and function of host DCs, resulting in increased alloactivation and proliferation of donor T cells in NOD2-/- allo-BMT recipients. Our results provide a possible cellular mechanism for recent clinical studies suggesting a regulatory role of NOD2 on the incidence of GVHD and transplant-related mortality in allo-HSCT recipients with SNPs in the gene locus encoding NOD2 (Holler et al., 2004, 2006; Elmaagacli et al., 2006).
###end p 19
###begin p 20
###xml 4 7 4 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 0 109 0 109 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NOD2<sup>&#8722;/&#8722;</sup> DCs have a higher activation status and increased ability to induce T cell proliferation during GVHD.</bold>
###xml 158 161 158 161 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 211 212 211 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 234 235 234 235 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 390 391 390 391 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k</sup>
###xml 398 399 398 399 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 460 461 460 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 752 753 752 753 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 771 772 771 772 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 829 832 829 832 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 874 875 874 875 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 894 895 894 895 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 932 933 932 933 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
NOD2-/- DCs have a higher activation status and increased ability to induce T cell proliferation during GVHD. Lethally irradiated (11 Gy) B6 WT versus B6 NOD2-/- allo-BMT recipients were transplanted with 5 x 106 B10BR TCD-BM + 2 x 106 B10BR T cells. Organs were harvested at day 7 after allo-BMT. Donor and host-derived DCs were distinguished by MHC class I disparity in flow cytometry (H2k vs. H2b). Combined data from two independent experiments are shown; n = 8/group. (A) Quantification of host DC subsets by flow cytometry. (B) Quantification of activation marker expression of host DCs by flow cytometry before allo-BMT and at day 7 after allo-BMT. (C) Histogram overlays of activation marker expression of host DCs during GVHD. (D) MLR using 105 splenic DCs (CD11+ selection) from B6 WT allo-BMT recipients versus B6 NOD2-/- allo-BMT recipients as stimulators and 105 B10BR T cells (CD5+ selection). Shown is the thymidine H3 uptake (cpm) between 48 and 72 h of MLR. Error bars indicate SEM.
###end p 20
###begin p 21
###xml 30 33 30 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 192 213 192 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">Watanabe et al., 2004</xref>
###xml 215 219 215 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib25">2006</xref>
###xml 221 225 221 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib26">2008</xref>
###xml 227 247 227 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">Strober et al., 2006</xref>
###xml 249 266 249 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib27">Yang et al., 2007</xref>
###xml 389 392 389 392 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 798 801 778 781 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1130 1151 1110 1131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib23">van Heel et al., 2005</xref>
###xml 1266 1269 1246 1249 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 34 38 <span type="species:ncbi:10090">mice</span>
###xml 1065 1071 <span type="species:ncbi:9606">humans</span>
In previous studies using NOD2-/- mice in inflammatory bowel disease models, it was suggested that increased TLR signaling led to a massively increased production of cytokines such as IL-12. (Watanabe et al., 2004, 2006, 2008; Strober et al., 2006; Yang et al., 2007) To determine whether increased cytokine/chemokine production is the underlying mechanism for the enhanced ability of NOD2-/- DCs to induce T cell proliferation, we performed allo-BMTs in the B10BR-->B6 model and measured cytokines/chemokines in serum with a multiplex system at day 7 after allo-BMT. We did not detect significant differences in serum levels of IFN-gamma, IL-1alpha, IL-1beta, IL-2, IL-6, IL-7, IL-9, IL-10, IL-12 p40, IL-12 p70, IL-15, IL-17, IP-10, LIX, MCP-1, MIG, MIP-1alpha, MIP-1beta, Rantes, and TNF in NOD2-/- allo-BMT recipients versus WT allo-BMT recipients (). Although serum levels were not different we cannot exclude differences in cytokine production in specified cell populations. However, our results are in agreement with recent data, which showed that APCs from humans with NOD2 SNPs do not have increased cytokine production (van Heel et al., 2005). Consequently, there might be alternative molecular mechanisms that can enhance APC function and activity in NOD2-/- allo-BMT recipients during inflammatory diseases such as colitis and GVHD.
###end p 21
###begin title 22
NOD2 deficiency of the hematopoietic system exacerbates experimental colitis
###end title 22
###begin p 23
###xml 381 406 381 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">Scheiffele and Fuss, 2002</xref>
###xml 542 545 542 545 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 633 636 633 636 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 674 682 674 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 A</xref>
###xml 710 713 710 713 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 744 747 740 743 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 863 866 859 862 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 906 909 898 901 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 925 933 917 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 B</xref>
###xml 1084 1087 1076 1079 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1137 1140 1125 1128 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1156 1171 1144 1159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5, C and D</xref>
###xml 1538 1541 1526 1529 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1548 1570 1536 1558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">Kobayashi et al., 2005</xref>
###xml 1681 1702 1669 1690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">Watanabe et al., 2004</xref>
###xml 1704 1708 1692 1696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib25">2006</xref>
###xml 1710 1714 1698 1702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib26">2008</xref>
###xml 1716 1736 1704 1724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">Strober et al., 2006</xref>
###xml 1738 1755 1726 1743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib27">Yang et al., 2007</xref>
###xml 1843 1846 1831 1834 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1905 1908 1893 1896 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 546 550 <span type="species:ncbi:10090">mice</span>
###xml 637 641 <span type="species:ncbi:10090">mice</span>
###xml 653 657 <span type="species:ncbi:10090">mice</span>
###xml 757 761 <span type="species:ncbi:10090">mice</span>
###xml 881 885 <span type="species:ncbi:10090">mice</span>
###xml 919 923 <span type="species:ncbi:10090">mice</span>
###xml 1102 1106 <span type="species:ncbi:10090">mice</span>
###xml 1150 1154 <span type="species:ncbi:10090">mice</span>
###xml 1542 1546 <span type="species:ncbi:10090">mice</span>
###xml 1847 1851 <span type="species:ncbi:10090">mice</span>
Next, we analyzed whether results from our GVHD experiments also apply to other inflammatory diseases. Because the pathophysiology of GVHD and inflammatory bowel disease has many similarities, we performed experiments using the TNBS (2,4,6-trinitrobenzenesulfonic acid) colitis model. TNBS colitis is a transmural inflammation often used as a model for inflammatory bowel disease (Scheiffele and Fuss, 2002). Administration of TNBS leads to modification of intestinal proteins that function as haptens. We rectally challenged B6 WT or B6 NOD2-/- mice with 5 mg TNBS in 50% ethanol. We found a significantly higher weight loss in NOD2-/- mice than in WT mice during colitis (Fig. 5 A). We next compared the NOD2-/--->WT chimeric to the WT-->NOD2-/- chimeric mice (90 d after syngeneic BMT) in the TNBS colitis model. We found significantly more weight loss in NOD2-/--->WT chimeric mice versus the WT-->NOD2-/- chimeric mice (Fig. 5 B). We harvested colons at day 3 after induction of colitis, performed histopathological analysis, and found significantly higher colitis scores in NOD2-/--->WT chimeric mice as compared with the WT-->NOD2-/- chimeric mice (Fig. 5, C and D). Our data demonstrate that NOD2 deficiency in the hematopoietic system, but not in the nonhematopoietic system, exacerbates both experimental GVHD and experimental TNBS colitis. These results suggest that loss of intestinal epithelial cell function causing impaired antibacterial resistance, which has been proposed as a mechanism for increased inflammation in NOD2-/- mice (Kobayashi et al., 2005), is not responsible for the increased GVHD and colitis. Our results are in agreement with previous findings (Watanabe et al., 2004, 2006, 2008; Strober et al., 2006; Yang et al., 2007) that found increased susceptibility to different types of experimental colitis in NOD2-/- mice, which was the result of the enhanced ability of NOD2-/- APCs to trigger inflammatory T cell responses.
###end p 23
###begin p 24
###xml 0 75 0 75 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NOD2 deficiency in the hematopoietic system regulates experimental colitis.</bold>
###xml 151 154 151 154 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 187 190 187 190 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 272 273 272 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 449 452 447 450 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 463 466 461 464 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 659 660 655 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 702 705 698 701 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 735 738 727 730 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 155 159 <span type="species:ncbi:10090">mice</span>
###xml 191 195 <span type="species:ncbi:10090">mice</span>
###xml 308 312 <span type="species:ncbi:10090">mice</span>
NOD2 deficiency in the hematopoietic system regulates experimental colitis. (A) TNBS colitis (5 mg TNBS in 50% ethanol) was induced in B6 WT or B6 NOD2-/- mice. Higher weight loss of NOD2-/- mice during colitis. Combined data from three independent experiments are shown; n = 12/group. (B-D) First, chimeric mice with NOD2 deficiency either in the hematopoietic system or in the nonhematopoietic system were created by syngeneic BMT (B6 WT-->B6 NOD2-/- or B6 NOD2-/--->B6 WT). After 90 d, TNBS colitis (5 mg TNBS in 50% ethanol) was induced. Colons were harvested at day 3 after induction of colitis. Combined data from two independent experiments are shown; n = 8/group. (B) Higher weight loss of NOD2-/--->WT chimera versus WT-->NOD2-/- chimera during colitis. (C) Hematoxylin and eosin-stained images of the colon at day 3 after induction of colitis. Bar, 200 microm. (D) Histological scoring showing increased colitis in the hematopoietic NOD2-deficient chimera. Error bars indicate SEM.
###end p 24
###begin title 25
###xml 4 7 4 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 8 12 <span type="species:ncbi:10090">mice</span>
NOD2-/- mice have intact resistance against experimental tumors
###end title 25
###begin p 26
###xml 88 106 88 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">Mayor et al., 2007</xref>
###xml 108 127 108 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">Holler et al., 2008</xref>
###xml 358 361 358 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 560 563 560 563 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 609 612 609 612 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 362 366 <span type="species:ncbi:10090">mice</span>
###xml 564 568 <span type="species:ncbi:10090">mice</span>
In response to mixed clinical results on a possible role of NOD2 in antitumor immunity (Mayor et al., 2007; Holler et al., 2008), we performed tumor challenges with hematologic and solid tumors. We studied the role of NOD2 in antitumor responses in two tumor models: acute myeloid leukemia (AML; C1498) and melanoma (B16). When we challenged B6 WT or B6 NOD2-/- mice intravenously with C1498 or B16, we found no significant differences in survival (unpublished data). Bioluminescence imaging demonstrated that early tumor growth was slightly reduced in B6 NOD2-/- mice in both models (). We conclude that NOD2-/- has no major role in antitumor immunity against C1498 AML and B16 melanoma.
###end p 26
###begin title 27
MATERIALS AND METHODS
###end title 27
###begin title 28

###end title 28
###begin title 29
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice and allo-BMT.
###end title 29
###begin p 30
###xml 126 129 126 129 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 136 158 136 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">Kobayashi et al., 2005</xref>
###xml 197 198 197 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 288 307 288 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib22">Terwey et al., 2005</xref>
###xml 309 332 309 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib28">Zakrzewski et al., 2006</xref>
###xml 334 338 334 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib29">2008</xref>
###xml 130 134 <span type="species:ncbi:10090">mice</span>
Animal protocols were approved by the Memorial Sloan-Kettering Cancer Center Institutional Animal Care and Use Committee. NOD2-/- mice (Kobayashi et al., 2005) were backcrossed to a B6 background (n = 11). BMT experiments and bioluminescent imaging was performed as described previously (Terwey et al., 2005; Zakrzewski et al., 2006, 2008).
###end p 30
###begin title 31
Flow cytometry and MLR.
###end title 31
###begin p 32
###xml 216 217 216 217 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 290 291 286 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
Most antibodies were obtained from BD. DCs were purified by positive selection with CD11c (N418) MicroBeads (Miltenyi Biotec) from digested spleens. Purity was between 90 and 95%. Splenic T cells were enriched by CD5+ selection and cocultured. After 48 h, thymidine (1 microCi [0.037 MBq] [3H]thymidine/well) was added and, after 72 h, thymidine uptake was measured (TopCount; Packard).
###end p 32
###begin title 33
Proliferation of CFSE-labeled T cells in vivo.
###end title 33
###begin p 34
T cells were selected using CD5 MicroBeads (Miltenyi Biotec), stained with 5 microM CFSE (Invitrogen), and transplanted into lethally irradiated allogeneic recipients.
###end p 34
###begin title 35
Measurement of cytokines and chemokines.
###end title 35
###begin p 36
###xml 49 54 <span type="species:ncbi:10090">Mouse</span>
Serum levels were determined using the Milliplex Mouse Cytokine/Chemokine Immunoassay (Millipore).
###end p 36
###begin title 37
Induction and assessment of TNBS colitis.
###end title 37
###begin p 38
###xml 65 90 65 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">Scheiffele and Fuss, 2002</xref>
###xml 167 192 167 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">Scheiffele and Fuss, 2002</xref>
Induction of TNBS colitis was performed as published previously (Scheiffele and Fuss, 2002). Severity of colitis was assessed using a semiquantitative scoring system (Scheiffele and Fuss, 2002).
###end p 38
###begin title 39
Statistics.
###end title 39
###begin p 40
Groupwise comparisons were done with the Mann-Whitney test, one-way ANOVA test, or the Wilcoxon matched pairs test where appropriate. Survival data were analyzed with the Mantel-Cox log-rank test.
###end p 40
###begin title 41
Online supplemental material.
###end title 41
###begin p 42
###xml 65 68 65 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 250 253 250 253 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 254 258 <span type="species:ncbi:10090">mice</span>
Fig. S1 shows that donor T cell subsets are not different in NOD2-/- versus WT allo-BMT recipients. In Fig. S2, the donor chimerism at day 90 is given. Fig. S3 shows serum levels of cytokines and chemokines during GVHD. Fig. S4 demonstrates that NOD2-/- mice have intact resistance against experimental tumors. Online supplemental material is available at .
###end p 42
###begin title 43
Supplementary Material
###end title 43
###begin title 44
[Supplemental Material]
###end title 44
###begin p 45
We would like to thank Renier Brentjens, Richard Flavell, Ivan J. Fuss, Atsushi Kitani, Katia Manova, Yan Nikhamin, Gabriel Nunez, Eric Pamer, Carles Ubeda-Morant, Joan Zhiqiong Yang, and James Young.
###end p 45
###begin p 46
This research was supported by National Institutes of Health grants RO1-HL069929 (to M. van den Brink), RO1-CA107096 (to M. van den Brink), RO1-AI080455 (to M. van den Brink), R01 HL084815 (to G.F. Murphy), and PO1-CA33049 (to M. van den Brink). Support was also received from the Ryan Gibson Foundation, the Elsa U. Pardee Foundation, the Byrne Fund, the Emerald Foundation, the Experimental Therapeutics Center of Memorial Sloan-Kettering Cancer Center funded by Mr. William H. Goodwin and Mrs. Alice Goodwin, the Commonwealth Foundation for Cancer Research, the Bobby Zucker Memorial Fund (to M. van den Brink), the Deutsche Forschungsgemeinschaft (to O. Penack), the Deutsche Krebshilfe (to I. Na and A. Ghosh), and the Alexander von Humboldt foundation (to K. Brandl).
###end p 46
###begin p 47
The authors have no conflicting financial interests.
###end p 47
###begin article-title 48
IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation.
###end article-title 48
###begin article-title 49
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human CARD4 protein is a novel CED-4/Apaf-1 cell death family member that activates NF-kappaB.
###end article-title 49
###begin article-title 50
###xml 22 27 <span type="species:ncbi:9606">human</span>
Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells.
###end article-title 50
###begin article-title 51
Toll-like receptors and T-helper-1/T-helper-2 responses.
###end article-title 51
###begin article-title 52
###xml 140 148 <span type="species:ncbi:9606">patients</span>
Mutations in innate immune system NOD2/CARD 15 and TLR-4 (Thr399Ile) genes influence the risk for severe acute graft-versus-host disease in patients who underwent an allogeneic transplantation.
###end article-title 52
###begin article-title 53
Loss of normal thymic repertoire selection and persistence of autoreactive T cells in graft vs host disease.
###end article-title 53
###begin article-title 54
Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation.
###end article-title 54
###begin article-title 55
Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination.
###end article-title 55
###begin article-title 56
NOD2/CARD15 polymorphisms in allogeneic stem-cell transplantation from unrelated donors: T depletion matters.
###end article-title 56
###begin article-title 57
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease.
###end article-title 57
###begin article-title 58
NODs: intracellular proteins involved in inflammation and apoptosis.
###end article-title 58
###begin article-title 59
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human Nod1 confers responsiveness to bacterial lipopolysaccharides.
###end article-title 59
###begin article-title 60
Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome.
###end article-title 60
###begin article-title 61
Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract.
###end article-title 61
###begin article-title 62
T cell activation by TLRs: a role for TLRs in the adaptive immune response.
###end article-title 62
###begin article-title 63
Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing.
###end article-title 63
###begin article-title 64
###xml 119 127 <span type="species:ncbi:9606">patients</span>
Single nucleotide polymorphisms in the NOD2/CARD15 gene are associated with an increased risk of relapse and death for patients with acute leukemia after hematopoietic stem-cell transplantation with unrelated donors.
###end article-title 64
###begin article-title 65
CARD15 mutations in Blau syndrome.
###end article-title 65
###begin article-title 66
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease.
###end article-title 66
###begin article-title 67
###xml 29 33 <span type="species:ncbi:10090">mice</span>
Induction of TNBS colitis in mice.
###end article-title 67
###begin article-title 68
Signalling pathways and molecular interactions of NOD1 and NOD2.
###end article-title 68
###begin article-title 69
CCR2 is required for CD8-induced graft-versus-host disease.
###end article-title 69
###begin article-title 70
Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease.
###end article-title 70
###begin article-title 71
NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses.
###end article-title 71
###begin article-title 72
Nucleotide binding oligomerization domain 2 deficiency leads to dysregulated TLR2 signaling and induction of antigen-specific colitis.
###end article-title 72
###begin article-title 73
###xml 85 89 <span type="species:ncbi:10090">mice</span>
Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis.
###end article-title 73
###begin article-title 74
###xml 5 20 <span type="species:ncbi:10090">transgenic mice</span>
NOD2 transgenic mice exhibit enhanced MDP-mediated down-regulation of TLR2 responses and resistance to colitis induction.
###end article-title 74
###begin article-title 75
Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation.
###end article-title 75
###begin article-title 76
Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors.
###end article-title 76
###begin p 77
###xml 0 19 0 19 <title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="78">Abbreviations used:</title>
###xml 19 27 19 27 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">allo-BMT</term>
###xml 27 55 27 55 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="79">allogenic BM transplantation</p>
###xml 27 55 27 55 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="79">allogenic BM transplantation</p></def>
###xml 19 55 19 55 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>allo-BMT</term><def><p textid="79">allogenic BM transplantation</p></def></def-item>
###xml 55 64 55 64 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">allo-HSCT</term>
###xml 64 114 64 114 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="80">allogeneic hematopoietic stem cell transplantation</p>
###xml 64 114 64 114 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="80">allogeneic hematopoietic stem cell transplantation</p></def>
###xml 55 114 55 114 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>allo-HSCT</term><def><p textid="80">allogeneic hematopoietic stem cell transplantation</p></def></def-item>
###xml 114 117 114 117 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AML</term>
###xml 117 139 117 139 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="81">acute myeloid leukemia</p>
###xml 117 139 117 139 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="81">acute myeloid leukemia</p></def>
###xml 114 139 114 139 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>AML</term><def><p textid="81">acute myeloid leukemia</p></def></def-item>
###xml 139 143 139 143 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GVHD</term>
###xml 143 168 143 168 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="82">graft-versus-host disease</p>
###xml 143 168 143 168 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="82">graft-versus-host disease</p></def>
###xml 139 168 139 168 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>GVHD</term><def><p textid="82">graft-versus-host disease</p></def></def-item>
###xml 168 171 168 171 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDP</term>
###xml 171 188 171 188 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="83">muramyl dipeptide</p>
###xml 171 188 171 188 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="83">muramyl dipeptide</p></def>
###xml 168 188 168 188 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>MDP</term><def><p textid="83">muramyl dipeptide</p></def></def-item>
###xml 188 191 188 191 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLN</term>
###xml 191 204 191 204 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="84">mesenteric LN</p>
###xml 191 204 191 204 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="84">mesenteric LN</p></def>
###xml 188 204 188 204 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>MLN</term><def><p textid="84">mesenteric LN</p></def></def-item>
###xml 204 207 204 207 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLR</term>
###xml 207 231 207 231 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="85">mixed leukocyte reaction</p>
###xml 207 231 207 231 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="85">mixed leukocyte reaction</p></def>
###xml 204 231 204 231 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>MLR</term><def><p textid="85">mixed leukocyte reaction</p></def></def-item>
###xml 231 235 231 235 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NOD2</term>
###xml 235 278 235 278 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="86">nucleotide-binding oligomerization domain 2</p>
###xml 235 278 235 278 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="86">nucleotide-binding oligomerization domain 2</p></def>
###xml 231 278 231 278 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>NOD2</term><def><p textid="86">nucleotide-binding oligomerization domain 2</p></def></def-item>
###xml 278 281 278 281 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SNP</term>
###xml 281 311 281 311 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="87">single nucleotide polymorphism</p>
###xml 281 311 281 311 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="87">single nucleotide polymorphism</p></def>
###xml 278 311 278 311 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>SNP</term><def><p textid="87">single nucleotide polymorphism</p></def></def-item>
###xml 311 317 311 317 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TCD-BM</term>
###xml 317 335 317 335 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="88">T cell&#8211;depleted BM</p>
###xml 317 335 317 335 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="88">T cell&#8211;depleted BM</p></def>
###xml 311 335 311 335 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>TCD-BM</term><def><p textid="88">T cell&#8211;depleted BM</p></def></def-item>
###xml 335 338 335 338 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TLR</term>
###xml 338 356 338 356 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="89">toll-like receptor</p>
###xml 338 356 338 356 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="89">toll-like receptor</p></def>
###xml 335 356 335 356 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term>TLR</term><def><p textid="89">toll-like receptor</p></def></def-item>
###xml 0 356 0 356 <def-list xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title textid="78">Abbreviations used:</title><def-item><term>allo-BMT</term><def><p textid="79">allogenic BM transplantation</p></def></def-item><def-item><term>allo-HSCT</term><def><p textid="80">allogeneic hematopoietic stem cell transplantation</p></def></def-item><def-item><term>AML</term><def><p textid="81">acute myeloid leukemia</p></def></def-item><def-item><term>GVHD</term><def><p textid="82">graft-versus-host disease</p></def></def-item><def-item><term>MDP</term><def><p textid="83">muramyl dipeptide</p></def></def-item><def-item><term>MLN</term><def><p textid="84">mesenteric LN</p></def></def-item><def-item><term>MLR</term><def><p textid="85">mixed leukocyte reaction</p></def></def-item><def-item><term>NOD2</term><def><p textid="86">nucleotide-binding oligomerization domain 2</p></def></def-item><def-item><term>SNP</term><def><p textid="87">single nucleotide polymorphism</p></def></def-item><def-item><term>TCD-BM</term><def><p textid="88">T cell&#8211;depleted BM</p></def></def-item><def-item><term>TLR</term><def><p textid="89">toll-like receptor</p></def></def-item></def-list>
Abbreviations used:allo-BMTallogenic BM transplantationallo-HSCTallogeneic hematopoietic stem cell transplantationAMLacute myeloid leukemiaGVHDgraft-versus-host diseaseMDPmuramyl dipeptideMLNmesenteric LNMLRmixed leukocyte reactionNOD2nucleotide-binding oligomerization domain 2SNPsingle nucleotide polymorphismTCD-BMT cell-depleted BMTLRtoll-like receptor
###end p 77
###begin title 78
Abbreviations used:
###end title 78
###begin p 79
allogenic BM transplantation
###end p 79
###begin p 80
allogeneic hematopoietic stem cell transplantation
###end p 80
###begin p 81
acute myeloid leukemia
###end p 81
###begin p 82
graft-versus-host disease
###end p 82
###begin p 83
muramyl dipeptide
###end p 83
###begin p 84
mesenteric LN
###end p 84
###begin p 85
mixed leukocyte reaction
###end p 85
###begin p 86
nucleotide-binding oligomerization domain 2
###end p 86
###begin p 87
single nucleotide polymorphism
###end p 87
###begin p 88
T cell-depleted BM
###end p 88
###begin p 89
toll-like receptor
###end p 89

